Escalation Study with Anti-CD 44 v 6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

@inproceedings{Tijink2006EscalationSW,
  title={Escalation Study with Anti-CD 44 v 6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus},
  author={BernardM. Tijink and Jan Buter and Remco de Bree and Guiseppe Giaccone and Margreet S. Lang and Alexander Staab and C. Rene ¤ Leemans and Guus A. M. S. van Dongen},
  year={2006}
}
Purpose:To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine. Bivatuzumab is a humanized monoclonal antibody directed against CD44v6, which previously seemed to be safe in phase I radioimmunotherapy trials, whereas the conjugated mertansine is a potent maytansine derivative. Experimental Design… CONTINUE READING